Showing results (601-610 of 2,823) with videos related to
Sort By:
Pageof 283
Cytotherapy|October 16, 2021
Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor eraAkira Ishii, Tomoyasu Jo, Yasuyuki Arai, et al.Cytotherapy|October 29, 2021
Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular ImmunotherapyHisham Abdel-Azim, Hema Dave, Kimberly Jordan, et al.Cytotherapy|April 11, 2022
Rapid potency assessment of autologous peripheral blood stem cells by intracellular flow cytometry: the PBSC-IL-3-pSTAT5 assayCarl Simard, Diane Fournier, Nicolas Pineault, et al.Cytotherapy|April 13, 2023
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.Cytotherapy|March 31, 2021
The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56Gitte Holmen Olofsson, Sara Ram Pedersen, Pia Aehnlich, et al.Cytotherapy|August 17, 2020
Conditioned media from mesenchymal stromal cells and periodontal ligament fibroblasts under cyclic stretch stimulation promote bone healing in mouse calvarial defectsKota Ogisu, Masahito Fujio, Shuhei Tsuchiya, et al.Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.Cytotherapy|April 9, 2021
Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspectiveBrooke M Helfer, Vladimir Ponomarev, P Stephen Patrick, et al.Cytotherapy|January 16, 2014
Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cellsOlga Zolochevska, Joseph Shearer, Jayne Ellis, et al.Cytotherapy|January 21, 2014
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of careFrancesco Saglio, Patrick J Hanley, Catherine M BollardPageof 283